Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pfs25 malaria vaccine - MVI

Next Previous
Drug Profile

Pfs25 malaria vaccine - MVI

Alternative Names: Malaria transmission-blocking Pfs25-Pfs25 conjugate vaccine; Pfs25 antigen; Pfs25 EPA; Pfs25 Pfs25; Pfs25 VLP; Pfs25 VLP-FhCMB; Pfs25-EPA/Alhydrogel; Transmission-blocking malaria vaccine - iBio/Fraunhofer

Latest Information Update: 22 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins Bloomberg School of Public Health; Malaria Vaccine Initiative; Sabin Vaccine Institute
  • Developer Fraunhofer USA Center for Molecular Biotechnology; National Institute of Allergy and Infectious Diseases
  • Class Antimalarials; Parasitic vaccines; Vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
  • 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Malaria(Prevention) in Mali (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top